Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option ...
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the fo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback